News

Medpage Today on MSN2mon
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC
Patients receiving the combination of 177 Lu-PSMA-617 and the androgen receptor pathway inhibitor (ARPI) lived a median ... School of Medicine in Palo Alto, California, pointed out that data ...
Healio29d
FDA expands Pluvicto indication for earlier use in patients with prostate cancer
Lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) received an expanded indication, which allows the radioligand therapy to be used after one androgen receptor pathway inhibitor (ARPI), as ...